REMUNERATION REPORT

of Evonik Industries AG



Remuneration report

The remuneration report outlines the principles of the remuneration system, which was most recently presented to the annual shareholders' meeting of Evonik Industries AG on May 25, 2022 and approved by the meeting (subsequently referred to as the remuneration system), and the remuneration of the members of the executive board and supervisory board for fiscal 2022. Detailed and individualized information on the amount and structure of the various components of the remuneration of the executive board and supervisory board is also provided. The report complies with the requirements of the Act Implementing the Second Shareholder Rights Directive (ARUG II) of December 12, 2019 and the recommendations of the German Corporate Governance Code in the version dated April 28, 2022.

1. Resolution approving the remuneration report for the previous fiscal year

The remuneration report compiled by Evonik Industries AG in accordance with the requirements of section 162 of the German Stock Corporation Act (AktG) on the remuneration awarded and due to present and former members of the executive board and supervisory board in the previous year (fiscal 2021) was approved by the shareholders' meeting on May 25, 2022 with the necessary majority. The executive board and supervisory board regard this vote as confirmation of the format used for the first time for the remuneration report 2021. It is therefore retained for the present remuneration report 2022.

2. Remuneration of members of the executive board

2.1 Changes to the remuneration system 2022 compared with the remuneration system 2020

The changes compared with the remuneration system approved by the shareholders' meeting on August 31, 2020 principally comprise the inclusion of a sustainability component in the long-term variable remuneration, the optional introduction of pension contributions in cash, the inclusion in the remuneration system of the share ownership guidelines, which have already been agreed in individual contracts, and the additional scope for the supervisory board to intervene in the variable remuneration components in exceptional circumstances.

2.2 Remuneration system Principles and objectives

The remuneration system for the executive board is designed to ensure that members receive appropriate remuneration for their tasks and responsibilities and to take direct account of the


performance of each member of the executive board and of the company. The structure of the remuneration system for the members of the executive board of Evonik Industries AG is geared to sustained value creation and performance-oriented management of the company.

Components and structure

In line with the remuneration system, the remuneration of members of the executive board comprises a fixed base salary, which takes account of the tasks and services performed by the respective member, a variable short-term component comprising an annual bonus, which is dependent on the attainment of the company's annual performance targets, and a long-term component linked directly to the increase in the value of the company as an incentive for sustained commitment to the company (LTI). The targets for the short- and long-term variable remuneration components are derived from the corporate strategy of Evonik Industries AG. In addition, the executive board members are granted the customary fringe benefits and a company pension plan. Overall, the remuneration supports the long-term development of the company.

Components of the remuneration system for the executive board

C01



Performance-unrelated components Fixed annual base salary

The fixed annual base salary is a cash payment for the fiscal year. It takes account of the scope of responsibility of each executive board member and is paid out in twelve equal installments.

Benefits in kind and other fringe benefits

As benefits in kind and other fringe benefits, members of the executive board receive a company car with a driver, the installation of telecommunications equipment, and an entitlement to an annual medical check-up. Executive board members may receive a rent subsidy if performance of their duties requires them to rent a second apartment. Benefits in kind are presented in this remuneration report at the values defined in the tax regulations.

Further, members of the executive board may receive additional remuneration for offices they hold in the interests of the company. Apart from fees for the attendance of meetings, insofar as such fees are paid to executive board members, such remuneration is deducted from their annual bonus or paid over to the company. In this remuneration report, remuneration for offices held in the interests of the company is included in other fringe benefits.

Company pension plan

A defined contribution system has been introduced as the standard pension plan. This is a capital-based system funded by provisions. The company credits a fixed annual amount to the pension account of each executive board member. This is 15 percent of their target remuneration, in other words, their fixed annual base salary and target bonus (variable short-term remuneration assuming 100 percent target attainment). The guaranteed annual return is 5 percent. The pension benefit comprises the amount that has accrued on the account, i.e., contributions credited to the account plus accumulated interest. In the event of death or

disability, the amount that would be available on the account on the member's 55th birthday, including projected contributions and interest, is calculated. Payment normally comprises a lifelong pension. Alternatively, executive board members may opt for disbursement of part of the capital (maximum 50 percent) in six to ten installments. At the request of a (former) executive board member and taking into account the company's economic interests, the supervisory board may decide that the capital should be paid out in full as a single lump sum. Such application must be submitted before the balance on the pension account is drawn. Where executive board members accrued pension entitlements prior to their appointment to the executive board, these are either integrated into the system as an initial contribution or continue to be managed separately. If an executive board member's contract ends before benefits are payable, no further contributions are credited to the account. However, it continues to earn interest at the common market interest rate based on the average interest paid by major German life insurers (at least 2.25 percent p.a.) until benefits are claimed.

Members of the executive board are entitled to pension benefits after they leave the company if they leave on or after reaching the individually agreed retirement age or if they leave as a result of permanent incapacity to work. In addition, Mr. Kullmann and Mr. Wessel can claim pension benefits from the date of premature termination or non-extension of their executive board contracts by the company, providing they do not give due cause for such termination. This claim also relates to pension entitlements they accrued prior to their appointment to the executive board. An arrangement that differs from the pension system has been agreed with Dr. Harald Schwager. He has been given a commitment that he will receive a lifelong pension of €40 thousand p.a. for each full year of service and a pro rata amount for each partial year of service.

For newly appointed executive board members, from 2023 onwards, the supervisory board has the option of agreeing on a pension allowance with the newly appointed member instead of a pension commitment. In this case, the amount of the pension allowance is 15 percent of the target annual remuneration (base salary plus target bonus), gross, and will be paid to the executive board member without being earmarked for a specific purpose.

Performance-related components Short-term variable remuneration

The performance-related annual bonus is dependent on the attainment of business targets measured by performance indicators (bonus factor) and the attainment of non-financial targets (performance factor). The bonus factor and performance factor are multiplied. The level of the bonus factor depends on the achievement of the agreed business targets and may be between 0 percent and 200 percent. The adjusted EBITDA margin, adjusted EBITDA, and free cash flow are defined as business targets. All parameters are measured against the long-term strategic objectives for the company based on the actual results in the calendar year. The development of plant safety and accident frequency and the severity of accidents in the fiscal year are also taken into account.

The performance factor rewards the attainment of the non-financial targets and can vary between 80 percent and 120 percent. The reference indicators are aligned to the performance objectives for the executive board and normally have a multi-year context within the target-setting framework, taking into consideration targets in areas such as strategy/portfolio, the efficiency of cost structures, and corporate culture, but the supervisory board may extend or change the targets for each topic if necessary.

If the non-financial targets and business objectives are achieved in full, the contractually agreed target bonus is paid. If the company's income falls short of the planned level, the bonus factor may—in the extreme case—be zero, regardless of personal attainment. In other words, it is conceivable that a bonus might not be paid for a specific year. The bonus is capped at 200 percent of the target bonus. The business and non-financial targets set for executive board members for the bonus and performance factors are agreed in writing at the start of each fiscal year between the supervisory board and each member of the executive board, and the level of attainment is determined by the supervisory board after the end of the year.

Long-term variable remuneration (LTI plans)

The members of the executive board receive long-term variable remuneration in the form of long-term incentive (LTI) plans. The general reference base for long-term remuneration is a sustained rise in the value of the company.

Performance is measured by the absolute performance of Evonik's share price and its performance relative to the MSCI World Chemicals IndexSM (or a comparable index). Based on the contractually agreed target amount, which is defined in euros, a number of virtual shares is calculated using the share price at the start of the performance period. This is based on the price in the last 60 trading days before the start of performance period. The performance period starts on January 1 of the grant year and runs for four years. At the end of the performance period, the starting price of Evonik shares is viewed against the average share price at the end of the performance period, plus any dividends

per share actually paid in this period. This is compared with the performance of the benchmark index (total shareholder return). Eligible participants are informed of the outcome after the end of the performance period. They can then opt to accept the payment calculated or to extend the performance period on a one-off basis for a further year. In this case, a renewed calculation is performed at the end of the extended performance period.

Since 2019, the intrinsic value of the LTI has been measured at the end of each year in the four-year performance period by comparing the starting price of Evonik shares with the average price of the shares at the end of each year, plus the dividends per share actually paid during the performance period. This is then compared with the performance of the benchmark index (total shareholder return). There is no longer an option to extend the performance period.

The relative performance may be between 70 percentage points and 130 percentage points. If the relative performance is below 70 percentage points, the relative performance factor is deemed to be zero. If the relative performance is greater than 130 percentage points, the relative performance factor is set at 130.

The payment is calculated by multiplying the relative performance by the number of virtual shares allocated and the average price of Evonik shares at the end of the performance period. Since 2019, the overall performance, and thus the amount to be paid at the end of the performance period, has been calculated as an average of the performance in each year.

The upper limit for these payments is set at 300 percent of the amount awarded to the individual.

Annual amount

Calculation of long-term remuneration from the 2019 LTI tranche

Annual amount

C02

| Virtual Evonik |
|----------------------|
| shares (calculated |
| from the target |
| amount and |
| share price at start |
| of period) |
| |
| |
| |

| No. of virtual shares |
|-----------------------|
| X |
| year-end price |
| X |
| "relative |
| performance" factor |
| (0 to 1.3) |
| |

No. of virtual shares

x
year-end price
x
"relative
performance" factor
(0 to 1.3)

Annual amount

Annual amount
n + 2

No. of virtual shares

X
year-end price

X
"relative
performance" factor
(0 to 1.3)

No. of virtual shares

X

year-end price

X

"relative
performance" factor
(0 to 1.3)

Cash settlement =
average of the annual
amounts
n to n + 3
(payment capped
at 300% of the
target amount)

The LTI system is to be revised again as from 2023. In the future, 80 percent of the intrinsic value will be determined by the performance of Evonik shares and 20 percent by the attainment of one or more sustainability targets.

For the share-based component, the intrinsic value of the LTI will be measured at the end of each year in the four-year performance period by comparing the starting price of Evonik shares with the average price of the shares at the end of the performance period plus the dividends per share actually paid during the performance period. This will then be compared with the performance of the benchmark index (total shareholder return).

The relative performance can range between 0 percentage points and 200 percentage points. If the relative performance is below O percentage points, the relative performance factor is deemed to be zero. If the relative performance is greater than 200 percentage points, the relative performance factor is set at 200 percent.

The payment is calculated by multiplying the relative performance by the number of virtual shares allocated and the average price of Evonik shares at the end of the performance period. The total performance of the share-based component is determined at the end of the performance period as an average of the performance in each year.

The sustainability component is determined separately on the basis of between one and three measurable ESG (environmental, social, governance) targets for Evonik. Before the allocation of each tranche, the supervisory board defines the exact annual targets, their relative weighting, and the target amounts for the calculation of 100 percent target attainment. Target attainment may range from 0 to 200 percent.

The specific sustainability targets are disclosed in the remuneration report in which the granting of the respective LTI tranche is reported. An explanation of how target attainment was determined for the individual sustainability targets is published retrospectively in the annual reporting process.

From 2023, there is an upper limit for these payments; this is set at 200 percent of the amount awarded to the individual.

For all allocated LTIs, the supervisory board has the option of setting a payment that deviates from the target attainment measured.

Calculation of long-term remuneration from the 2023 LTI tranche

C03

a) Share-based payment (weighting 80%)

| Virtual Evonik shares |
|-----------------------|
| (calculated from |
| 80% of the target |
| amount and |
| share price at start |
| of period) |
| |

| Annual amount n | Annual amount n + 1 | Annual amoun n + 2 |
|--|--|---|
| | | |
| No. of virtual shares x year-end price x "relative performance" factor (0 to 2) | No. of virtual shares x year-end price x "relative performance" factor (0 to 2) | No. of virtual sha x year-end price x "relative performance" fac (0 to 2) |
| | | |

| Annual amount n + 2 No. of virtual shares | | |
|---|--|--|
| x x year-end price year-end price x x x "relative "relative performance" factor performance" factor | 7 | 7 |
| x x year-end price year-end price x x x "relative "relative performance" factor performance" factor | | |
| | x year-end price x "relative performance" factor | x year-end price x "relative performance" factor |

Settlement amount = averaσe of the annual amounts n to n + 3(payment capped at 200% of 80% of the target amount)

b) Sustainability component (weighting 20%)

Definition of between one and three targets, each with a target curve before allocation of an LTI tranche. Calculation of target attainment at end of the performance period. (Target evaluation per target: 0% to 200%)

Settlement amount = weighted target attainment of the individual sustainability targets x 20% of the target amount

c) Determination of the total cash settlement

Settlement amount share-based component + settlement amount sustainability component

Total cash settlement calculated by adding the separate settlement amounts

Determination of maximum remuneration

The maximum remuneration of members of the executive board is defined as follows in the remuneration system and is based on the maximum possible performance-related and performance-unrelated remuneration components, including service cost for the company pension plan:

Chairman of the executive board: €9,700 thousand
Deputy chairman: €7,200 thousand
Chief human resources officer: €5,200 thousand
Chief financial officer: €5,200 thousand

Explanation of how the remuneration is determined

The remuneration is reviewed regularly by the supervisory board, where appropriate on the basis of remuneration reports from independent consultants. These reviews examine the structure and level of remuneration of the executive board, particularly in comparison with the external market, and also in relation to remuneration elsewhere in the company. The external comparison uses peer groups comprising, on the one hand, comparable companies in the chemicals sector and, on the other hand, companies listed on the MDAX/DAX indices. The assessment of the appropriateness of the remuneration compared with remuneration elsewhere in the company starts by determining the average remuneration at the first management level below the executive board and the remuneration of the workforce as a whole. This is then compared

with the peer group described above and its appropriateness relative to the market is reviewed, taking into account the development of remuneration over time. The supervisory board defines the senior management level and relevant workforce and how the remuneration is assessed in relation to these groups. If this reveals a need to adjust the remuneration system or the level or structure of remuneration, the executive committee of the supervisory board submits a corresponding proposal to the full supervisory board for a decision. If the supervisory board involves an external remuneration expert, it makes sure the expert is independent.

Cap on termination benefits in the event of premature termination of term of office

In conformance with the German Corporate Governance Code, the employment contracts with all members of the executive board provide for a cap on termination benefits. If a member's term of office is prematurely terminated, payments may not exceed two years' remuneration, including variable remuneration components. In no case is remuneration payable for periods beyond the remaining term of the contract. The contracts specify that no termination benefits are payable if an executive board member's contract is terminated for reasons for which he or she is responsible. The cap on termination benefits is based on total remuneration, including fringe benefits in the previous fiscal year and, where appropriate, the anticipated total remuneration for the current fiscal year.

Share ownership guidelines

There is a contractual requirement for executive board members to acquire Evonik shares equivalent to the value of at least 100 percent of their fixed annual base salary within three years from 2019 or from their initial appointment, and to hold these shares for the duration of their period of service on the executive board.

Claw-back clause

In case a member of the executive board commits a serious breach of his or her statutory duties or internal rules of conduct, contracts with members of the executive board contain a contractual clause providing for the reimbursement or offsetting, in full or in part, of any variable remuneration components paid to the member of the executive board for the performance period in question (claw-back clause).

Temporary deviation from the remuneration system

In exceptional circumstances, it is possible to temporarily deviate from individual components of the described remuneration system if this is necessary in the interests of the long-term good of the company. Deviation from the remuneration system is only possible on the basis of a resolution by the supervisory board. The components of the remuneration system from which deviation is possible in exceptional circumstances are the short- and long-term remuneration and the defined average relationship between the remuneration elements.

2.3 Remuneration of the members of the executive board for 2022

This section provides details of the remuneration of the members of the executive board of Evonik Industries AG. It contains information on the total remuneration of the executive board, the targets for variable remuneration and their attainment, and an individualized breakdown of the remuneration of each member of the executive board in 2022.

Performance-unrelated components Base salary

| Base salary | T01 |
|---------------------|-----------|
| in€ | 2022 |
| Christian Kullmann | 1,400,000 |
| Dr. Harald Schwager | 1,130,000 |
| Thomas Wessel | 800,000 |
| Ute Wolf | 800,000 |

Fringe benefits

In 2022, fringe benefits comprised taxation of company cars and, in some cases, remuneration for other offices held (see table Remuneration awarded/due T10 p.12). Fees for other offices held, excluding attendance fees, are deducted from the short-term variable remuneration for 2022.

Pension commitments

In 2022, the service cost for members of the executive board totaled \leq 2,735 thousand based on IFRS.

The present value of pension obligations for members of the executive board was €20,705 thousand based on IFRS.

To enhance understanding of the pension contributions actually paid in the fiscal year, for the executive board members covered

by the standard pension plan, the newly earned pension and interest components are disclosed.

Service cost and present value of pension obligations

T02

| | IFF | IFRS | | Annual contributions to the Evonik Board Pension Plan | | |
|----------------------------------|--------------|--|-----|---|------------------------------|--|
| | Service cost | Present value of the defined bene- fit obligation (DBO) Service cost as of Dec. 31 | | Interest | Total annual contribution | |
| in €′000 | | 2022 | | | 2022 | |
| Christian Kullmann | 925 | 7,548 | 390 | 138 | 528 | |
| Dr. Harald Schwager ^a | 932 | 3,384 | | | | |
| Thomas Wessel | 441 | 6,329 | 210 | 82 | 292 | |
| Ute Wolf | 437 | 3,444 | 210 | 99 | 309 | |
| Total | 2,735 | 20,705 | | | | |

^a Not part of the standard pension plan.

Disclosures on exceptional circumstances in 2022 Application of the performance criteria for short-term variable remuneration

In view of the cluster of various unforeseen developments (the war in Ukraine, the energy crisis, the coronavirus crisis, supply chain disruption, inflation, the threat of recession, the impact of climate change), the basic conditions taken into consideration when establishing the targets for the short- and long-term remuneration of the executive board members no longer prevail. As a result, application of a performance criterion for the target set for short-term variable remuneration as used in the past no longer represents an appropriate benchmark for target attainment and, if retained, could act as a false incentive. The company's supervisory board has therefore decided that an inflation-adjusted sales figure will be used for the calculation of the short-term remuneration 2022 for the target "adjusted EBITDA margin."

Without this adjustment for the target indicator "adjusted EBITDA margin," there would be a risk that this would not be commensurate with the executive board's performance.

Modified performance threshold for LTI payout

Furthermore, the supervisory board has resolved that, as provided for by the remuneration system, for the outstanding exercise periods for the LTI tranches 2018 through 2022, with effect from January 1, 2023, i.e., for the first time for the payment in 2023, the lower limit for relative performance should be set at 0 percent instead of 70 percent, as provided for directly in the remuneration system for the LTI plans from 2023. Without this adjustment, the value of the LTI tranche 2018 would be reduced to zero, and there would also be a significant loss of value for the LTI tranches 2019 through 2022.

The supervisory board considers these corrections to the remuneration of the executive board within the framework of the remuneration system approved by the shareholders' meeting to be appropriate in order to pay the executive board members remuneration that is commensurate with their tasks and performance and to set the right incentives for the benefit of the company.

Performance-related remuneration—short-term variable remuneration (annual bonus) Business targets based on performance indicators (bonus factor)


As performance criteria for fiscal 2022, the supervisory board defined the adjusted EBITDA margin, adjusted EBITDA, and the free cash flow. For all performance indicators, specific targets were derived from the strategic corporate planning, and a corresponding performance band with upper and lower limits was defined. In addition, the weighting of each indicator was set at 30 percent. Accident frequency, accident severity, and plant safety were set as a further target with a weighting of 10 percent.

Non-financial targets (performance factor)

To determine the performance factor for 2022, team targets were determined, with a focus on strategy/portfolio, performance/costs, and sustainability.

Overview of short-term variable remuneration and how it is calculated





Non-financial targets for fiscal 2022

C05

| Target description | Target attainment |
|---|-------------------|
| Strategy/portfolio Portfolio transformation through acquisitions, divestments, and expansion of the growth engines Impact of crisis-induced changes in operating conditions on corporate strategy Sales growth by the innovation growth drivers Continuation of "One Culture for One Evonik" | 1.13 |
| 2. Performance/costs Compensation of factor costs Supply Chain Management@Evonik project Ongoing development of the functions towards the industry benchmark Savings potential at Technology & Infrastructure Strengthening pricing power Definition of sustainability KPIs and integration into the performance management process | 1.15 |
| 3. Sustainability Present and adopt the sustainability strategy CO₂ mitigation (scopes 1 & 2) and estimate of the impact of decisions on key performance indicators Details of the functional strategy of the business lines with a focus on handprint and footprint | 1.17 |
| Total performance factor | 1.15 |

Determination of target attainment in 2022

The targets set for fiscal 2022 and the target attainment calculated for the annual bonus are presented in the following table and apply uniformly for all executive board members:

Target and target attainment for short-term variable remuneration (annual bonus)

T03

| Performance indicator | Weighting | Target (100%) | Actual value | Target evaluation |
|-------------------------------------|-----------|------------------|------------------|-------------------|
| Adjusted EBITDA margin ^a | 30.0% | 16.90% | 14.76% | 55.4% |
| Adjusted EBITDA | 30.0% | €2,525.0 million | €2,490.1 million | 96.5% |
| Free cash flow | 30.0% | €1,000.0 million | €785.4 million | 64.2% |
| Accident performance ^b | 10.0% | | | 120.0% |
| Total bonus factor | | | | 76.5% |
| Performance factor | | | | 1.15 |
| Overall target attainment | | | | 88.3% |

^a See also: Application of the performance criteria for short-term variable remuneration.

Target amounts and level of the annual bonus for 2022

Target, minimum, and maximum amounts for the annual bonus

T04

| | 2022 | | | |
|---------------------|------|---------------|-------------|--|
| in€ | Min. | Target (100%) | Max. (200%) | |
| Christian Kullmann | 0 | 1,200,000 | 2,400,000 | |
| Dr. Harald Schwager | 0 | 750,000 | 1,500,000 | |
| Thomas Wessel | 0 | 600,000 | 1,200,000 | |
| Ute Wolf | 0 | 600,000 | 1,200,000 | |

The overall target attainment of 88.3 percent results in the following settlement amounts (excluding the deduction of any fees received for other offices held):

| Annual bonus payments | T05 |
|-----------------------|-----------|
| in€ | 2022 |
| Christian Kullmann | 1,060,000 |
| Dr. Harald Schwager | 662,500 |
| Thomas Wessel | 530,000 |
| Ute Wolf | 530,000 |

b Based on group-wide accident performance. Specific reasons for the accident performance and the consequences of accidents, especially fatal accidents, may be taken into account, along with plant safety.

Performance-related remuneration—long-term variable remuneration (LTI) Preliminary information on the granting of LTI tranche 2023


As outlined in the remuneration system, a sustainability component with a weighting of 20 percent of the total LTI is provided for from 2023. The supervisory board has already set the exact targets and their relative weighting. The targets for 2023 comprise measurable targets from the Evonik Group's environmental and social context. The specific targets set include a target for CO₂ reduction in the Evonik Group (40 percent weighting), a target to increase the proportion of sustainable products—known as Next Generation Solutions—(40 percent weighting), and a target increase in a social index (20 percent weighting). The social index covers aspects of health, learning, and diversity. These sustainability targets, including the target amounts, will be outlined in detail in next year's remuneration report.

Information on the granting of LTI tranche 2022

As the performance criterion for the LTI tranche 2022, the supervisory board set the long-term increase in corporate value measured by

- the absolute performance of Evonik's share price and
- the relative performance of Evonik's share price (based on total shareholder return) compared with a selected equity index (MSCI World Chemicals IndexSM).

Timeline LTI 2022



The share price used to calculate the allocation of virtual Evonik shares for the LTI 2022 was €27.80. They were allocated on May 16, 2022. This date is used to determine the grant value on the date of the legally binding commitment. The start value

determined for the MSCI World Chemicals IndexSM was 746.116. The following table shows the contractual target amounts and allocation of virtual shares for each member of the executive board:

Information on allocation of the LTI 2022

| in€ | Target amount (based on 100% target attainment) | Maximum amount (300%) | No. of virtual shares allocated | Grant value |
|---------------------|---|--------------------------|---------------------------------|-------------|
| Christian Kullmann | 1,650,000 | 4,950,000 | 59,353 | 1,297,457 |
| Dr. Harald Schwager | 1,200,000 | 3,600,000 | 43,165 | 943,587 |
| Thomas Wessel | 900,000 | 2,700,000 | 32,374 | 707,696 |
| Ute Wolf | 900,000 | 2,700,000 | 32,374 | 707,696 |

Provisional determination of target attainment for LTI tranches 2018 and 2019

The LTI tranches 2018 and 2019 were dependent, on the one hand, on the absolute share price performance of Evonik shares and, on the other hand, on the price performance of Evonik

shares compared with a selected equity index (MSCI World Chemicals IndexSM). Up to and including the 2018 tranche, target attainment was measured solely at the end of the performance period. The 2018 tranche was the last tranche with two exercise periods. In 2021, which was the first exercise period for the 2018

tranche, the intrinsic value of this tranche was zero. Therefore, the performance period was automatically extended by one year. From the 2019 tranche, the intrinsic value of the LTI is measured at the end of each year in the four-year performance period. There is no longer an option to extend the performance period.

Provisional determination of the settlement amount for the 2018 LTI tranche: 2nd exercise period

T07

| | Virtual shares allocated | Share price (average of the last 60 trading days in 2022) | Relative performance ^a | Settlement amount |
|---------------------|--------------------------|---|--------------------------------------|-------------------|
| Christian Kullmann | 39,949 | €18.42 | 49% | €360,590 |
| Dr. Harald Schwager | 31,959 | €18.42 | 49% | €288,457 |
| Thomas Wessel | 23,969 | €18.42 | 49% | €216,343 |
| Ute Wolf | 23,969 | €18.42 | 49% | €216,343 |

a 1+ performance of Evonik shares on a TSR basis in percent—performance of the MSCI World Chemicals Index In percent. See also: Modified performance threshold for LTI payout.

Provisional determination of the settlement amount for the 2019 LTI tranche

| | Virtual shares allocated | Annual amount 2019 ª (year-end price: €25.24; rel. perf.: 90%) | Annual amount 2020 ^a (year-end price: €24.14; rel. perf.: 76%) | Annual amount 2021 ^a (year-end price: €27.80; rel. perf.: 64%) | Annual amount 2022ª (year-end price: €18.42; rel. perf.: 50%) | Settlement amount ^b |
|---------------------|--------------------------|--|---|---|---|--------------------------------|
| Christian Kullmann | 64,504 | €1,465,283 | €1,183,439 | €1,147,667 | €594,082 | €1,097,618 |
| Dr. Harald Schwager | 46,912 | €1,065,658 | €860,688 | €834,667 | €432,060 | €798,269 |
| Thomas Wessel | 35,184 | €799,250 | €645,504 | €626,000 | €324,045 | €598,700 |
| Ute Wolf | 35,184 | €799,250 | €645,504 | €626,000 | €324,045 | € 598,700 |

a Calculation of the annual amount: no. of virtual shares x relative performance factor (rounded up to full virtual shares) x year-end price (average of the last 60 trading days in the year). See also: Modified performance threshold for LTI payout.

b Settlement amount = average of the annual amounts 2019 through 2022.

Overview of LTI tranches 2017 through 2022

The fair values of the LTI tranches 2017 through 2022 as of the date of the legally binding commitment are shown in the next table:

LTI tranches a

| T 0 0 | |
|-------|--|
| 109 | |
| 107 | |

| | 2017 | | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | |
|---------------------|-----------------------|----------|-----------------------|----------|-----------------------|----------|-----------------------|---------|-----------------------|----------|-----------------------|---------|
| | No. of virtual shares | in €′000 | No. of virtual shares | in €′000 | No. of virtual shares | in €′000 | No. of virtual shares | in€′000 | No. of virtual shares | in €′000 | No. of virtual shares | in€′000 |
| Christian Kullmann | 41,787 | 1,033 | 39,949 | 1,018 | 64,504 | 1,429 | 65,372 | 1,303 | 68,351 | 1,918 | 59,353 | 1,297 |
| Dr. Harald Schwager | 12,090 | 299 | 31,959 | 814 | 46,912 | 1,039 | 47,544 | 948 | 49,710 | 1,395 | 43,165 | 944 |
| Thomas Wessel | 27,203 | 672 | 23,969 | 611 | 35,184 | 779 | 35,658 | 711 | 37,283 | 1,046 | 32,374 | 708 |
| Ute Wolf | 27,203 | 672 | 23,969 | 611 | 35,184 | 779 | 35,658 | 711 | 37,283 | 1,046 | 32,374 | 708 |
| Total | 108,283 | 2,676 | 119,846 | 3,054 | 181,784 | 4,026 | 184,232 | 3,673 | 192,627 | 5,405 | 167,266 | 3,657 |

^a The date of the legally binding commitment corresponds to the grant date.

In 2022, the total expense for all LTI tranches for the executive board was \in 3,861 thousand. The breakdown of the expense was as follows: \in 1,347 thousand for Mr. Kullmann, \in 1,006 thousand for Dr. Schwager, \in 754 thousand for Mr. Wessel, and \in 754 thousand for Ms. Wolf.

Claw-back clause

In 2022, the supervisory board did not utilize the option—where available—to withhold or claw back variable remuneration components.

Remuneration awarded/due for 2022

The following table presents a breakdown of the remuneration awarded/due to individual members of the executive board in 2022. In accordance with the provisions of section 162 of the German Stock Corporation Act (AktG), the disclosure of the remuneration awarded/due comprises the amounts fully earned in the reporting period. Accordingly, an earnings-oriented perspective is applied. As a departure from this principle, the long-term remuneration is disclosed on the basis of the amount paid, i.e., the settlement amount within the reporting period.

The remuneration-related disclosures are subdivided into fixed and variable remuneration components. The fixed remuneration components comprise the performance-unrelated fixed annual base salary and fringe benefits. The variable remuneration components are subdivided into one-year and multi-year variable remuneration. The remuneration disclosed for the reporting period comprises the fixed remuneration components earned and paid out in the reporting period, the multi-year variable remuneration due and paid in the fiscal year (payments relating to the 2017 and 2018 LTI tranches), plus the one-year variable remuneration fully earned in the reporting period, which will be paid out in the spring of the following year (2023). Although the service cost for the company pension plan is not classified as remuneration that is awarded or due pursuant to section 162 of the German Stock Corporation Act (AktG), for the sake of transparency, it is disclosed under total remuneration in the following table (as defined in section 162 AktG).

Remuneration awarded/due

| | Christian Kullmann Chairman of the Executive Board | | Dr. Harald Schwager Deputy Chairman of the Executive Board | | Thomas Wessel Chief Human Resources Officer | | Ute Wolf Chief Financial Officer | |
|---|---|-------|---|-------|--|-------|--|-------|
| _ | in €′000 | in % | in €′000 | in % | in €′000 | in % | in €′000 | in % |
| Fixed base salary | 1,400 | 55.5 | 1,130 | 61.8 | 800 | 58.9 | 800 | 58.4 |
| Fringe benefits | 61 | 2.4 | 51 | 2.8 | 73 | 5.4 | 39 | 2.8 |
| Total | 1,461 | 58.0 | 1,181 | 64.6 | 873 | 64.3 | 839 | 61.3 |
| One-year variable remuneration (annual bonus) | 1,060 | 42.0 | 648 | 35.4 | 485 | 35.7 | 530 | 38.7 |
| Multi-year variable remuneration (LTI) | | | | | | | | |
| LTI 2017 through 2021 | _ | _ | _ | _ | | _ | _ | _ |
| LTI 2018 through 2021 | _ | _ | _ | _ | | _ | _ | - |
| Total variable remuneration | 1,060 | 42.0 | 648 | 35.4 | 485 | 35.7 | 530 | 38.7 |
| Total remuneration (as defined in section 162 AktG) | 2,521 | 100.0 | 1,829 | 100.0 | 1,358 | 100.0 | 1,369 | 100.0 |
| Service cost | 925 | | 932 | | 441 | | 437 | |
| Total remuneration (including service cost) | 3,446 | | 2,761 | | 1,799 | | 1,806 | |

^a Some fees for other offices reported as fringe benefits are deducted from the one-year variable remuneration. 2022: Schwager €15 thousand, Wessel €45 thousand.

Disclosure on the relative development of executive board remuneration compared to the remuneration of the workforce and the company's earnings performance

The following overview outlines the development of the remuneration awarded/due to individual executive board members in the reporting period. This is compared with the development of selected earnings indicators for the company and the Evonik Group in the reference period (from 2020; this will be built up successively until the comparison covers a five-year period). Further, it is compared with the change in the average remuneration of the workforce, based on full-time equivalents (FTEs). The average remuneration of the workforce is derived from the remuneration components paid in the fiscal year, excluding any special payments. Variable remuneration components are included on the basis of the provisions established for fiscal 2022. The relevant workforce comprises permanent employees at all consolidated companies in Germany, excluding the members of the executive board, apprentices, and interns.

Remuneration awarded/due to the executive board compared to the development of the remuneration of the workforce and the company's earnings performance

| the remuneration of the workforce and the company s | earnings performa | nce | | | 111 |
|--|-------------------|-------------|-------|-------------|-------|
| Remuneration of corporate officers in €′000 | 2020 | Change in % | 2021 | Change in % | 2022 |
| Present executive board members: | | | | | |
| Christian Kullmann | 2,756 | 29.2 | 3,561 | -29.2 | 2,521 |
| Dr. Harald Schwager | 1,979 | 24.7 | 2,468 | -25.9 | 1,829 |
| Thomas Wessel | 1,492 | 25.8 | 1,877 | -27.7 | 1,358 |
| Ute Wolf | 1,468 | 27.5 | 1,872 | -26.9 | 1,369 |
| Former executive board members: | | | | | |
| Dr. Wolfgang Colberg | 292 | | 292 | 5.1 | 307 |
| Dr. Klaus Engel | 2,008 | -61.9 | 765 | 1.0 | 773 |
| Dr. Thomas Haeberle | 347 | 3.5 | 359 | 3.1 | 370 |
| Dr. Dahai Yu | 0 | | 16 | 1,087.5 | 190 |
| Average remuneration of the workforce in € '000 | | | | | |
| Permanent employees in Germany | 82 | 8.5 | 89 | -4.5 | 85 |
| Company's earnings performance b | | | | | |
| Adjusted EBITDA of the Evonik Group in € million c | 1,906 | 25.0 | 2,383 | 4.5 | 2,490 |
| Adjusted EBTIDA margin of the Evonik Group in % | 15.6 | 2 | 15.9 | -15.1 | 13.5 |
| Free cash flow ^d of the Evonik Group in € million | 780 | 22 | 950 | -17.4 | 785 |
| Net income (+)/net loss (−) of Evonik Industries AG in € million (HGB) | -40 | 1,930 | 732 | -130.5 | -223 |

^a The relative changes in the average cash payments may be influenced by a variety of factors and may vary across the executive board and the workforce and over time. These factors include, for example, changes in the composition of the workforce, different salary increases for exempt and non-exempt employees, the integration and carve-out of business activities, and personnel-related measures.

^b For the first time, the earnings figures published for the relevant fiscal year are shown, rather than the figures restated in the following fiscal year.

^c Earnings before financial result, taxes, depreciation and amortization, after adjustments, continuing operations.

d Cash flow from operating activities, continuing operations, less cash outflows for investment in intangible assets, property, plant and equipment.

Compliance with the maximum remuneration for 2022

Compliance with the maximum remuneration is derived from the total remuneration components for fiscal 2022. Since the four-year performance period means that target attainment and thus the settlement amount of the LTI tranche allocated in 2022 will

only be known after the end of fiscal 2025, it will only be possible to report definitively on compliance with the maximum remuneration for fiscal 2022 in the remuneration report on 2025. However, it is already foreseeable that even if the maximum amount for the LTI 2022 is achieved, remuneration will not exceed the defined maximum level.

Compliance with the maximum remuneration

| in €′000 | Defined maximum remuneration | Fixed annual salary and fringe benefits 2022 | One-year variable remuneration ^a | Multi-year variable remuneration ^b | Service cost 2022 | Total |
|---------------------|------------------------------------|--|---|---|----------------------|-------|
| Christian Kullmann | 9,700 | 1,461 | 1,060 | | 925 | 3,446 |
| Dr. Harald Schwager | 7,200 | 1,181 | 648 | _ | 932 | 2,761 |
| Thomas Wessel | 5,200 | 873 | 485 | _ | 441 | 1,799 |
| Ute Wolf | 5,200 | 839 | 530 | _ | 437 | 1,806 |

^a Bonus for fiscal 2022; disbursement in 2023 after deduction of fees for other offices held in 2022.

^b The LTI allocated in 2022 will be measured and paid out in 2026.

Compliance with the share ownership guidelines

As of December 31, 2022, all executive board members were in compliance with the share ownership guidelines and had acquired shares in Evonik Industries AG on their own account for at least 100 percent of their fixed annual base salary.

Benefits in connection with termination of executive board contracts

No executive board contracts were terminated in the reporting period.

Other disclosures

T12

As of December 31, 2022, there were no loans or advances to members of the executive board. Moreover, in the reporting period, none of the executive board members were allocated or awarded any benefits by third parties in connection with their function as a member of the executive board.

Remuneration awarded/due to former members of the executive board for 2022

The total remuneration of former members of the executive board and their surviving dependents was €3,141 thousand in 2022. The following table contains a breakdown of remuneration awarded/due to former members of the executive board whose period of service ended within the past ten fiscal years, including the relative percentages in accordance with section 162 AktG. It does not include payments to executive board members whose service ended more than ten years ago, pension benefits from previous employers, and pension benefits to surviving dependents. These payments amounted to a total of €1,501 thousand in 2022 (+2.2 percent compared with the previous year).

Remuneration awarded/due

| | Dr. Wolfgang Member of the Ex Apr. 1, 2009–Sep | ecutive Board | Dr. Klaus En Member of the Exec Jan. 1, 2007 – Dec. Chairman of the Exec Jan. 1, 2009 – May 2 | utive Board 31, 2008 cutive Board | Dr. Thomas Ha Member of the Exec Apr. 1, 2011–Jun. | utive Board | Dr. Dahai Y Member of the Execu Apr. 1, 2011–Jun. 3 | tive Board |
|---------------------------------|---|---------------|---|---|---|-------------|--|------------|
| | in €′000 | in % | in €′000 | in % | in €′000 | in % | in€′000 | in % |
| Pension benefits ^a | 307 | 100 | 773 | 100 | 354 | 96 | 190 | 100 |
| Disbursement of DC ^b | | | _ | _ | 16 | 4 | _ | _ |
| Total remuneration | 307 | 100 | 773 | 100 | 370 | 100 | 190 | 100 |

^a Excluding transfers from previous employer.

113

^b Deferred compensation: additional pension benefits accrued through deferred compensation arrangements.

Remuneration of members of the supervisory board

3.1 Remuneration system

The remuneration of the supervisory board is governed by section 15 of the articles of incorporation of Evonik Industries AG.

The remuneration system takes account of the responsibilities and scope of activities of the members of the supervisory board. Given its duty to oversee the executive board in its management of the business, the supervisory board makes a contribution to promoting the business strategy and to the long-term development of the company. In addition to reimbursement of their expenses and value-added tax payable on their remuneration and expenses, the members of the supervisory board receive a fixed annual payment. Their remuneration does not include a variable component. In view of the special nature of the remuneration of the supervisory board, which is awarded for activities that differ fundamentally from the work of employees and of the Evonik Group, it is not possible to conduct a comparison with the remuneration of employees.

The remuneration system for the supervisory board is regularly reviewed by the administration. The remuneration takes into

account, in particular, the time commitment of the members of the supervisory board and the remuneration awarded to the supervisory boards of other comparable companies.

Different levels of fixed annual remuneration are paid to the chairman (€250 thousand), his deputy (€175 thousand), and other members of the supervisory board (€100 thousand).

The chairman of the executive committee receives additional remuneration of €60 thousand, the deputy chairwoman €45 thousand and the other members €35 thousand each. The chairman of the audit committee receives additional remuneration of €90 thousand, the deputy chairwoman €60 thousand, and the other members €50 thousand each. The chairman of the finance and investment committee receives additional remuneration of €60 thousand, the deputy chairwoman €45 thousand, and the other members €35 thousand each. The chairwoman of the innovation and research committee receives additional remuneration of €30 thousand, the deputy chairman €20 thousand, and the other members €15 thousand each. The chairmen of the nomination committee and the mediation committee receive additional remuneration of €20 thousand each, the deputy chairpersons receive €10 thousand each, and the other members €10 thousand each. Entitlement to the additional remuneration for work on the mediation committee only applies if the committee is actually convened during the fiscal year.

Further, members of the supervisory board receive a fee of €1 thousand for each meeting of the supervisory board and its committees that they attend. If several meetings are held on the same day, this fee is only paid once.

Members who only serve on the supervisory board for part of a fiscal year receive remuneration on a pro rata basis. This also applies for increases in the remuneration of the chairman of the supervisory board and his deputy and any increased remuneration paid for membership of or chairing a committee.

3.2 Remuneration of the members of the supervisory board for 2022 Remuneration awarded/due for 2022

The following table presents a breakdown of the remuneration awarded/due to individual members of the supervisory board in 2022. The amounts disclosed comprise the fixed remuneration and remuneration for membership of committees for fiscal 2022, which will only be paid out in the following year (2023). Therefore, an earnings-oriented perspective is applied. The attendance fees are amounts actually paid in 2022.

Remuneration awarded/due

T14

| | Fixed remuneration Rem | | Remuneration for membershi | ip of a committee | Attendance fees | | Total | |
|---|------------------------|------|----------------------------|-------------------|-----------------|------|---------|-------|
| | in€′000 | in % | in€′000 | in % | in€′000 | in % | in€′000 | in % |
| Bernd Tönjes | 250 | 63.5 | 130 | 33.0 | 14 | 3.5 | 394 | 100.0 |
| Karin Erhard | 175 | 63.9 | 90 | 32.8 | 9 | 3.3 | 274 | 100.0 |
| Martin Albers | 100 | 55.5 | 70 | 38.9 | 10 | 5.6 | 180 | 100.0 |
| Prof. Barbara Albert | 100 | 73.0 | 30 | 21.9 | 7 | 5.1 | 137 | 100.0 |
| Jens Barnhusen (until March 31, 2022) | 25 | 62.5 | 13 | 32.5 | 2 | 5.0 | 40 | 100.0 |
| Prof. Aldo Belloni | 100 | 53.8 | 75 | 40.3 | 11 | 5.9 | 186 | 100.0 |
| Birgit Biermann (until May 25, 2022) | 42 | 59.2 | 25 | 35.2 | 4 | 5.6 | 71 | 100.0 |
| Hussin El Moussaoui | 100 | 82.0 | 15 | 12.3 | 7 | 5.7 | 122 | 100.0 |
| Werner Fuhrmann | 100 | 95.2 | | | 5 | 4.8 | 105 | 100.0 |
| Prof. Barbara Grunewald | 100 | 62.9 | 50 | 31.4 | 9 | 5.7 | 159 | 100.0 |
| Alexandra Krieger (from May 26, 2022) | 67 | 59.8 | 40 | 35.7 | 5 | 4.5 | 112 | 100.0 |
| Martin Kubessa | 100 | 95.2 | | | 5 | 4.8 | 105 | 100.0 |
| Frank Löllgen (until May 25, 2022) | 42 | 61.8 | 23 | 33.8 | 3 | 4.4 | 68 | 100.0 |
| Cedrik Neike | 100 | 97.1 | _ | _ | 3 | 2.9 | 103 | 100.0 |
| Martina Reisch | 100 | 82.0 | 15 | 12.3 | 7 | 5.7 | 122 | 100.0 |
| Gerhard Ribbeheger | 100 | 62.1 | 50 | 31.1 | 11 | 6.8 | 161 | 100.0 |
| Michael Rüdiger | 100 | 42.0 | 125 | 52.5 | 13 | 5.5 | 238 | 100.0 |
| Dr. Thomas Sauer | 100 | 62.9 | 50 | 31.4 | 9 | 5.7 | 159 | 100.0 |
| Gerd Schlengermann (from April 1, 2022) | 75 | 63.0 | 38 | 31.9 | 6 | 5.1 | 119 | 100.0 |
| Harald Sikorski (from May 26, 2022) | 67 | 60.9 | 37 | 33.6 | 6 | 5.5 | 110 | 100.0 |
| Angela Titzrath | 100 | 63.7 | 50 | 31.8 | 7 | 4.5 | 157 | 100.0 |
| Dr. Volker Trautz | 100 | 59.2 | 60 | 35.5 | 9 | 5.3 | 169 | 100.0 |
| Ulrich Weber | 100 | 65.0 | 45 | 29.2 | 9 | 5.8 | 154 | 100.0 |
| Total | 2,243 | | 1,031 | | 171 | | 3,445 | |

For members who joined or left the supervisory board during 2022, the amounts are calculated on a pro rata basis.

Disclosure on the relative development of supervisory board remuneration compared to the remuneration of the workforce and the company's earnings performance

The following overview outlines the development of the remuneration awarded/due to individual supervisory board members for the relevant fiscal year. This is compared with the development of selected earnings indicators for the company and the Evonik Group in the reference period (from 2020; this will be built up successively until the comparison covers a five-year period). Further, it is compared with the change in the average remuneration of the workforce based on full-time equivalents (FTEs). The average remuneration of the workforce is derived from the remuneration components paid in the fiscal year, excluding any special payments. Variable remuneration components are included on the basis of the provisions established for fiscal 2022. The relevant workforce comprises permanent employees at all consolidated companies in Germany, excluding the members of the executive board, apprentices, and interns.

Other disclosures

As of December 31, 2022, there were no loans or advances to members of the supervisory board. In 2022 the members of the supervisory board did not receive any remuneration for services provided personally, especially consulting and referral services.

Finally, third-party financial loss insurance cover is provided for each member of the supervisory board to cover their statutory liability arising from their work on the supervisory board. In the event of a claim, this provides for a deductible of 10 percent of the damage, up to one-and-a-half times the individual member's fixed annual remuneration.

Remuneration awarded/due to the supervisory board compared to the development of the remuneration of the workforce and the company's earnings performance

| Remuneration of corporate officers in €′000 | 2020 | Change in % | 2021 | Change in % | 2022 |
|--|-------|-------------|-------|-------------|-------|
| Present members of the supervisory board: | | | | | |
| Bernd Tönjes | 395 | 1.5 | 401 | -1.7 | 394 |
| Karin Erhard | 211 | 35.5 | 286 | -4.2 | 274 |
| Martin Albers | 180 | 1.1 | 182 | -1.1 | 180 |
| Prof. Barbara Albert | 136 | 0.7 | 137 | _ | 137 |
| Jens Barnhusen (until March 31, 2022) | 154 | 3.2 | 159 | -74.8 | 40 |
| Prof. Aldo Belloni | 153 | 15.0 | 176 | 5.7 | 186 |
| Birgit Biermann (from September 1, 2020 until May 25, 2022) | 56 | 198.2 | 167 | -57.5 | 71 |
| Hussin El Moussaoui | 121 | 0.8 | 122 | _ | 122 |
| Werner Fuhrmann (from June 3, 2021) | _ | | 60 | 75.0 | 105 |
| Prof. Barbara Grunewald | 158 | 0.6 | 159 | _ | 159 |
| Alexandra Krieger (from May 26, 2022) | _ | | _ | | 112 |
| Martin Kubessa | 104 | 1.0 | 105 | _ | 105 |
| Frank Löllgen (until May 25, 2022) | 160 | 3.8 | 166 | -59.0 | 68 |
| Cedrik Neike (from June 3, 2021) | | | 61 | 68.9 | 103 |
| Martina Reisch | 121 | 0.8 | 122 | _ | 122 |
| Gerhard Ribbeheger (from April 1, 2021) | | | 118 | 36.4 | 161 |
| Michael Rüdiger | 168 | 26.2 | 212 | 12.3 | 238 |
| Dr. Thomas Sauer | 158 | 0.6 | 159 | _ | 159 |
| Gerd Schlengermann (from April 1, 2022) | _ | | _ | | 119 |
| Harald Sikorski (from May 26, 2022) | _ | | _ | | 110 |
| Angela Titzrath | 157 | 1.3 | 159 | -1.3 | 157 |
| Dr. Volker Trautz | 169 | 2.4 | 173 | -2.3 | 169 |
| Ulrich Weber | 153 | 2.6 | 157 | -1.9 | 154 |
| Average remuneration of the workforce a in €′000 | | | | | |
| Permanent employees in Germany | 82 | 8.5 | 89 | -4.5 | 85 |
| Company's earnings performance b | | | | | |
| Adjusted EBITDA of the Evonik Group in € million ^c | 1,906 | 25.0 | 2,383 | 4.5 | 2,490 |
| Adjusted EBTIDA margin of the Evonik Group in % | 15.6 | 1.9 | 15.9 | -15.1 | 13.5 |
| Free cash flow ^d of the Evonik Group in € million | 780 | 21.8 | 950 | -17.4 | 785 |
| Net income (+)/net loss (−) of Evonik Industries AG in € million (HGB) | -40 | 1,930.0 | 732 | -130.5 | -223 |

^a The relative changes in the average cash payments may be influenced by a variety of factors and may vary across the workforce and over time. These factors include, for example, changes in the composition of the workforce, different salary increases for exempt and non-exempt employees, the integration and carve-out of business activities, and personnel-related measures.

b For the first time, the earnings figures published for the relevant fiscal year are shown, instead of figures restated in the following fiscal year.

^c Earnings before financial result, taxes, depreciation and amortization, after adjustments, continuing operations.

d Cash flow from operating activities, continuing operations, less cash outflows for investment in intangible assets, property, plant and equipment.

Independent Auditor's Report

Note: This is a translation of the German original. Solely the original text in German language is authoritative.

To Evonik Industries AG, Essen

REPORT ON THE AUDIT OF THE REMUNERATION REPORT

We have audited the attached remuneration report of Evonik Industries AG, Essen, for the financial year from 1 January to 31 December 2022, including the related disclosures, prepared to meet the requirements of Section 162 AktG [Aktiengesetz: German Stock Corporation Act].

Responsibilities of Management and the Supervisory Board

The management and the Supervisory Board of Evonik Industries AG are responsible for the preparation of the remuneration report, including the related disclosures, in accordance with the requirements of Section 162 AktG. The management and the Supervisory Board are also responsible for such internal control as they have determined necessary to enable the preparation of the remuneration report that is free from material misstatement, whether due to fraud (i.e., fraudulent financial reporting and misappropriation of assets) or error.

Auditor's responsibilities

Our responsibility is to express an opinion on this remuneration report, including the related disclosures, based on our audit. We conducted our audit in accordance with the German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer [Institute of Public Auditors

in Germany] (IDW). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the remuneration report, including the related disclosures, is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts, including the related disclosures, in the remuneration report. The procedures selected depend on the auditor's professional judgement. This includes an assessment of the risks of material misstatement, whether due to fraud or error, in the remuneration report, including the related disclosures. In assessing these risks, the auditor considers the internal control system relevant for the preparation of the remuneration report, including the related disclosures. The objective is to plan and perform audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management and the Supervisory Board, as well as evaluating the overall presentation of the remuneration report, including the related disclosures.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Opinion

In our opinion, on the basis of the knowledge obtained in the audit, the remuneration report for the financial year from 1 January to 31 December 2022, including the related disclosures, complies in all material respects with the financial reporting requirements of Section 162 AktG.

Other matter – formal examination of the remuneration report

The substantive audit of the remuneration report described in this independent auditor's report includes the formal examination of the remuneration report required by Section 162 (3) AktG, including issuing an assurance report on this examination. As we have issued an unqualified opinion on the substantive audit of the remuneration report, this opinion includes the conclusion that the disclosures pursuant to Section 162 (1) and (2) AktG have been made, in all material respects, in the remuneration report.

Limitation of liability

The terms governing this engagement, which we fulfilled by rendering the aforesaid services to Evonik Industries AG, are set out in the General Engagement Terms for Wirtschaftsprüfer and Wirtschaftsprüfungsgesellschaften [German Public Auditors and Public Audit Firms] as amended on 1 January 2017. By taking note of and using the information as contained in this auditor's report, each recipient confirms to have taken note of the terms and conditions laid down therein (including the limitation of liability of EUR 4 million for negligence under Clause 9 of the General Engagement Terms) and acknowledges their validity in relation to us.

Essen, 1 March 2023

KPMG AG

Wirtschaftsprüfungsgesellschaft [Original German version signed by:]

Dr. Hain Dr. Ackermann
Wirtschaftsprüfer Wirtschaftsprüferin
[German Public Auditor] [German Public Auditor]

